Last reviewed · How we verify

NCT03304561

The Effect of Contralateral Limb Training on Functional Outcomes in Patients With ACL Reconstruction

Completed NA Last updated 5 February 2018
What this trial tests

NA trial testing Traditional rehabilitation in Anterior Cruciate Ligament Reconstruction in 36 participants. Completed in 30 October 2017.

Timeline
1 October 2016
Primary endpoint
1 August 2017
30 October 2017

Quick facts

Lead sponsorHacettepe University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment36
Start date1 October 2016
Primary completion1 August 2017
Estimated completion30 October 2017
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Hacettepe University

Who can join

Adults 18 to 45, any sex, with Anterior Cruciate Ligament Reconstruction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Quadriceps and hamstring muscle strenghts have important role in returning to sport after ACL reconstruction and one of the main focus of rehabilitation is to improve strenght of these muscles. With the strenghtening of the contralateral limb (cross-over training) we aimed to improve the strenght of the quadriceps

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Traditional rehabilitation

Trials testing the same drug.

Other recruiting trials for Anterior Cruciate Ligament Reconstruction

Currently open trials in the same condition.

Other Hacettepe University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03304561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing